Last updated: September 27, 2026
Durezol, the branded ophthalmic corticosteroid difluprednate 0.05% emulsion, is a mature U.S. eye-care product with limited remaining exclusivity and substantial generic substitution risk. The product received FDA approval in 2008 and has moved from an originator-led market to a generic-dominated or generic-contested market. Bausch + Lomb is the current U.S. commercial owner and manufacturer identified in the product labeling, but it does not report Durezol revenue as a separate line item. [1]
The commercial outlook depends on brand retention, physician preference for the emulsion formulation, postoperative ophthalmology volume, reimbursement, and the number and pricing behavior of generic difluprednate suppliers.
What is Durezol and how is it used?
Durezol is difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid used for:
- Treatment of inflammation and pain associated with ocular surgery
- Treatment of endogenous anterior uveitis
The FDA approved Durezol on June 26, 2008, under New Drug Application 022212. The product is a sterile ophthalmic emulsion rather than a conventional suspension. Its active ingredient is a fluorinated prednisolone derivative with high anti-inflammatory potency. [1]
What makes Durezol commercially distinct?
Durezol competes on potency, emulsion delivery, and dosing convenience relative to older ophthalmic corticosteroids. Its principal branded and generic alternatives include:
| Product |
Active ingredient |
Typical commercial position |
| Durezol |
Difluprednate 0.05% |
Premium branded corticosteroid emulsion |
| Generic difluprednate |
Difluprednate 0.05% |
Direct substitutable competitor |
| Pred Forte |
Prednisolone acetate 1% |
Established lower-cost corticosteroid |
| Lotemax |
Loteprednol etabonate |
Lower-risk steroid positioning |
| Prednisolone sodium phosphate |
Prednisolone phosphate |
Alternative topical steroid |
Durezol’s emulsion formulation can support a premium prescription price, but that advantage weakens when generic difluprednate products receive pharmacy-level substitution and payer coverage.
When did Durezol lose market exclusivity?
Durezol’s regulatory exclusivity expired many years ago. The drug was approved as a new dosage form and formulation of a known corticosteroid rather than as a new chemical entity. Its core FDA exclusivity period was therefore shorter than the five-year period generally associated with a qualifying new chemical entity.
| Event |
Date or status |
| FDA approval |
June 26, 2008 |
| NDA |
022212 |
| Likely three-year formulation exclusivity window |
Through approximately June 2011 |
| First generic competition |
Publicly reported in the early 2020s |
| Current status |
Mature branded product facing generic competition |
The expiration of regulatory exclusivity did not automatically eliminate all potential patent protection. Generic entry depended on the patent listings in the FDA Orange Book, any Paragraph IV certifications, litigation, and commercial decisions by ANDA applicants. [2]
Does Durezol have remaining market exclusivity?
Durezol does not have meaningful remaining regulatory exclusivity in the United States. Any current protection is more likely to arise from:
- Brand recognition
- Prescriber familiarity
- Formulation quality
- Manufacturing consistency
- Contracting and distribution
- Physician preference for the branded product
- Patient or payer restrictions on substitution
These factors can preserve some branded sales after patent and regulatory exclusivity expire, but they generally cannot prevent long-term generic price erosion.
What patents protect Durezol?
Durezol’s historical patent estate centered on difluprednate and its ophthalmic formulation. The relevant protection was directed to the active compound, ophthalmic compositions, emulsions, and methods of treating ocular inflammation.
The commercial importance of those patents has declined because the product is now a mature medicine and generic difluprednate products have entered the U.S. market. The public FDA label identifies Durezol as difluprednate ophthalmic emulsion 0.05%, but the current label does not create an independent period of market exclusivity. [1]
What formulation patents protect difluprednate?
Potentially relevant formulation claims include:
- A sterile ophthalmic emulsion containing difluprednate
- Stabilization of the corticosteroid in an aqueous vehicle
- Particle-size and dispersion control
- Preservative systems
- pH and viscosity ranges
- Packaging and delivery characteristics
These claims can create technical hurdles for a generic applicant, but they are less commercially decisive after ANDA approval. Generic applicants can design around expired or narrow formulation claims, challenge listed patents through Paragraph IV certifications, or use alternative excipients and manufacturing processes.
How strong is the Durezol patent estate?
The Durezol patent estate is commercially weak as a barrier to generic entry. The reasons are:
- The product has been marketed since 2008.
- The principal regulatory exclusivity period expired long ago.
- Generic difluprednate products have reached the U.S. market.
- The product is a small-molecule ophthalmic drug, not a biologic.
- Manufacturing complexity does not create the same protection as an active blocking patent.
The remaining value is primarily operational. Sterile ophthalmic emulsion manufacturing requires validated facilities, quality controls, preservative and container-closure testing, and consistent product performance. Those requirements can slow entry or limit the number of reliable suppliers, but they do not restore exclusivity.
What is the Orange Book status of Durezol?
Durezol is listed in the FDA Orange Book under NDA 022212. The Orange Book remains the primary source for current patent listings, patent-use codes, dosage-form information, and therapeutic-equivalence ratings. [2]
The commercial record indicates that Durezol is no longer protected by an effective regulatory exclusivity period that would prevent ANDA approval. The central Orange Book question is therefore not whether the brand has a remaining exclusivity period, but whether any listed patents or patent-use codes affect specific generic approvals.
For a branded ophthalmic product, Orange Book exposure can involve:
- Composition-of-matter patents
- Formulation patents
- Method-of-use patents
- Pediatric exclusivity
- Patent certifications filed by ANDA applicants
- Therapeutic-equivalence ratings for generic products
Durezol’s remaining Orange Book position does not appear to prevent generic competition.
Which companies are challenging Durezol?
Generic competition comes from ANDA sponsors marketing difluprednate ophthalmic emulsion 0.05%. Publicly reported U.S. generic activity has included companies such as Dr. Reddy’s Laboratories and other generic ophthalmic manufacturers. Product availability can change as suppliers enter, exit, or experience manufacturing or regulatory issues.
The most important competitive distinction is between:
- Authorized or branded Durezol supplied by Bausch + Lomb
- FDA-approved generic difluprednate products
- Other topical corticosteroids used instead of difluprednate
No major, continuing Paragraph IV litigation has become a defining commercial event for Durezol. The market appears to have transitioned through the ordinary generic-entry process rather than through a high-value patent settlement that materially delayed competition.
What is the FDA regulatory status of Durezol?
Durezol remains an FDA-approved prescription ophthalmic corticosteroid. The approved dosage form is a 0.05% ophthalmic emulsion. The product carries corticosteroid class risks, including elevated intraocular pressure, delayed wound healing, secondary infection, and cataract formation with prolonged use. [1]
The regulatory profile has several commercial implications:
- It is a prescription product, limiting direct consumer substitution.
- It is a small-molecule drug, so ANDA approval is the principal generic pathway.
- It is not a biologic, so biosimilar regulation does not apply.
- Generic products can receive therapeutic-equivalence ratings if they meet FDA requirements.
- Ophthalmic emulsion approval requires more than simple active-ingredient matching because formulation performance and product quality are material.
What generic entry risks exist for Durezol?
Generic substitution is the largest financial risk. Generic entry affects Durezol through three channels.
Price erosion
Generic difluprednate products typically launch at lower prices than the brand. Net brand pricing can decline through payer pressure, pharmacy substitution, rebates, and formulary exclusion.
Volume migration
Prescriptions can migrate from Durezol to generic difluprednate without a physician changing the active ingredient. This is more damaging than therapeutic substitution because it directly attacks the brand’s prescription base.
Therapeutic substitution
Prednisolone acetate, loteprednol, and other corticosteroids can be used for overlapping indications. Ophthalmologists may choose these products based on cost, postoperative protocols, severity of inflammation, or formulary status.
The risk is highest in routine postoperative cases. Brand retention is more plausible in complex patients, patients with prior response to Durezol, and practices that standardize on the branded product.
How does Durezol compare with competing ophthalmic steroids?
| Attribute |
Durezol |
Prednisolone acetate |
Loteprednol |
| Active ingredient |
Difluprednate |
Prednisolone acetate |
Loteprednol etabonate |
| Formulation |
Emulsion |
Suspension |
Suspension or gel formulations depending on product |
| Brand maturity |
Mature |
Mature |
Mature |
| Generic pressure |
High |
High |
High |
| Main advantage |
Potency and emulsion delivery |
Broad familiarity and low cost |
Steroid-risk positioning |
| Main commercial risk |
Direct generic difluprednate substitution |
Commodity pricing |
Premium price and competition |
Durezol has a stronger product differentiation story than a simple commodity ophthalmic steroid, but that differentiation is insufficient to protect price once a therapeutically equivalent generic is available.
What licensing deals affected Durezol?
Durezol was initially associated with Sirion Therapeutics and was later commercialized through the Alcon and Novartis ophthalmic businesses. Bausch + Lomb subsequently became associated with the U.S. product portfolio following the transfer of certain ophthalmic assets from Novartis.
The ownership history is commercially relevant because it shows that Durezol has been managed as part of a broader ophthalmology portfolio rather than as a standalone growth asset. Portfolio ownership can preserve distribution and physician access, but it does not change the product’s mature exclusivity position.
Bausch + Lomb’s public filings identify Durezol among its ophthalmic prescription products, but the company does not disclose separate Durezol revenue, gross margin, or operating profit. [3]
What is Durezol’s financial trajectory?
Durezol’s financial trajectory is best characterized as:
- Originator growth after the 2008 launch
- Portfolio expansion under major ophthalmology companies
- Maturity before generic entry
- Revenue and price pressure following generic difluprednate availability
- Long-tail branded demand supported by physician familiarity and distribution
Bausch + Lomb reports company-level revenue, not a separate Durezol sales figure. As a result, public financial statements do not support a precise product-level revenue forecast. [3]
What drives Durezol revenue?
| Revenue driver |
Directional effect |
| Cataract and other ophthalmic surgery volume |
Positive |
| Generic difluprednate availability |
Negative |
| Brand reimbursement |
Positive |
| Pharmacy substitution |
Negative |
| Physician preference |
Positive |
| Lower-cost prednisolone use |
Negative |
| Supply reliability |
Positive |
| Premium pricing |
Negative if payer resistance increases |
The product’s revenue exposure is likely modest relative to Bausch + Lomb’s total portfolio, which includes contact lenses, surgical products, prescription pharmaceuticals, and consumer eye-care products. Durezol is therefore unlikely to determine the company’s overall financial trajectory. It can still contribute attractive cash flow if manufacturing costs remain low and a meaningful branded prescription base survives.
What manufacturing and intellectual-property barriers remain?
The main barriers are technical rather than legal:
- Sterile ophthalmic manufacturing
- Emulsion uniformity
- Particle-size control
- Container-closure integrity
- Preservative compatibility
- Stability testing
- Batch-to-batch consistency
- FDA quality-system compliance
These requirements can produce supply shortages or limit the number of dependable generic suppliers. They do not provide durable market exclusivity unless supported by enforceable, unexpired patent claims.
Geographic protection is also limited. U.S. FDA approval and Orange Book listings do not automatically establish protection in Europe, Japan, Canada, or emerging markets. Separate national approvals, patent rights, reimbursement systems, and local generic competition determine commercial performance outside the United States.
What patent litigation affects Durezol?
Durezol does not have a widely reported litigation profile comparable to major blockbuster drugs with repeated Paragraph IV challenges, patent settlements, or authorized-generic launches. The principal legal risk has been ordinary generic entry against a mature ophthalmic product.
The absence of major public litigation does not eliminate patent risk. It means that the commercial outcome has been driven more by the age of the product, generic availability, and market pricing than by an extended patent dispute.
What are the likely generic launch scenarios?
Scenario 1: Broad generic penetration
Multiple generic suppliers remain active, pharmacy substitution increases, and Durezol becomes a limited branded product. This is the most likely long-term outcome.
Scenario 2: Limited supplier competition
Only a small number of manufacturers maintain reliable supply. Bausch + Lomb retains part of the brand market, while generic prices remain above commodity levels because ophthalmic emulsion manufacturing is technically demanding.
Scenario 3: Brand retention in selected segments
Durezol remains preferred in uveitis, high-inflammation postoperative cases, or practices with established protocols. Volume declines, but the brand preserves a premium niche.
The likely outcome is a combination of the first and third scenarios: broad generic pressure with residual branded demand in selected clinical settings.
Key Takeaways
- Durezol is difluprednate ophthalmic emulsion 0.05%, approved by the FDA in 2008.
- Its regulatory exclusivity expired long ago, and generic difluprednate competition is established.
- Bausch + Lomb is associated with the current U.S. branded product.
- Durezol’s patent estate is no longer a strong commercial barrier to entry.
- Formulation and sterile-manufacturing complexity may limit reliable generic supply but do not restore exclusivity.
- No separate Durezol revenue is disclosed in Bausch + Lomb public filings.
- The product’s financial trajectory is mature and declining under generic pressure, with residual value from brand loyalty, physician preference, and ophthalmic surgery demand.
- Durezol is not a biologic and has no biosimilar risk. Its relevant competitive risks are ANDA-based generic substitution and therapeutic substitution by other corticosteroids.
FAQs
Is Durezol still under patent protection?
Durezol no longer has meaningful regulatory exclusivity. Any remaining patent relevance must be assessed through the current FDA Orange Book and individual patent status, but generic difluprednate availability shows that the historical estate does not block market competition.
Is generic difluprednate equivalent to Durezol?
FDA-approved generic difluprednate products must satisfy applicable requirements for pharmaceutical equivalence and bioequivalence. Therapeutic equivalence depends on the FDA rating for the specific approved product.
Does Durezol face biosimilar competition?
No. Durezol is a small-molecule ophthalmic drug. Its competitors follow the ANDA generic pathway, not the biosimilar pathway.
Who owns the Durezol brand?
The U.S. product is associated with Bausch + Lomb. The commercial history includes earlier ownership and commercialization through Sirion Therapeutics, Alcon, and Novartis-related ophthalmology operations.
Will Durezol remain commercially viable after generic entry?
Yes, but as a mature branded product rather than an exclusivity-protected growth asset. Its remaining viability depends on physician preference, reimbursement, product availability, and the clinical value assigned to its emulsion formulation.
References
- U.S. Food and Drug Administration. (2008). Durezol (difluprednate ophthalmic emulsion) 0.05% prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Bausch + Lomb Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
